Mineralys Therapeutics, Inc. (MLYS) DCF Valuation

A meaningful DCF fair value isn't available for Mineralys Therapeutics, Inc. (MLYS) — its free-cash-flow and net-debt profile makes a standard discounted-cash-flow model unreliable (common for loss-makers and high-net-debt or recently-public companies), and no analyst DCF is published. Explore your own assumptions with the editable model below.

The FMP figure is a third-party point estimate. Its cash-flow forecast, discount rate, terminal growth, and valuation date are not included in the stored response, so TGMCharts presents it only as a reference—not as an intrinsic-value conclusion or price target.

Discounted Cash Flow

An editable DCF model isn't available for MLYS (insufficient free-cash-flow data).